.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,258,952

« Back to Dashboard

Details for Patent: 6,258,952

Title: Thermally stable trimetrexates and processes for producing the same
Abstract:The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P1(#2) and having a triclinic cell with dimensions of about a=7.699 .ANG., b=9.606 .ANG. and c=13.012 .ANG. is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline , is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.
Inventor(s): Stogniew; Martin (Blue Bell, PA), Grafe; Ingomar (Nurnberg, DE), Morsdorf; Johann (Langenzenn, DE)
Assignee: MedImmune Oncology, Inc. (West Conshohocken, PA)
Filing Date:Nov 09, 1999
Application Number:09/436,708
Claims:1. A method of producing 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate comprising:

a. preparing a crude trimetrexate base from trimetrexate acetate hydrate;

b. recrystallizing the crude trimetrexate base with dimethyl formamide (DMF) to produce a pure trimetrexate-DMF adduct;

c. converting the trimetrexate-DMF adduct to trimetrexate hydrochloride; and

d. converting trimetrexate hydrochloride to pure, crystalline trimetrexate monohydrate.

2. The method of claim 1 wherein step (a) is carried out in water, aliphatic C.sub.2 to C.sub.4 alcohols, or a mixture thereof.

3. The method of claim 2 wherein the solvent is a mixture of n-butanol and water.

4. The method of claim 3 wherein the n-butanol and water are in a ratio of from 1:1 to 10:1.

5. The method of claim 1 wherein step (a) comprises preparing a solution of trimetrexate acetate in a basic mixture of n-butanol and water; heating said solution in the presence of a catalytic amount of sodium metabisulfite; filtering the solution; further heating the solution to a temperature of about 50 to 90.degree. C.; and adding aqueous ammonia to crystallize crude trimetrexate base.

6. The method of claim 5 wherein the filtering is carried out at a pressure of about 1 bar.

7. The method of claim 5 which further comprises cooling the solution to room temperature after the crude trimetrexate base crystallizes, filtering the crude trimetrexate base, and washing the crude trimetrexate base.

8. The method of claim 7 wherein the crude trimetrexate base is washed with ethanol, water or a mixture thereof.

9. The method of claim 1 wherein step (b) comprises dissolving the crude trimetrexate base in a solvent comprising dimethyl formamide; heating the DMF solution; adding a C.sub.2 to C.sub.4 alcohol; and cooling the DMF solution to a temperature at which the trimetrexate-DMF adduct crystallizes.

10. The method of claim 9 which further comprises filtering the trimetrexate-DMF adduct.

11. The method of claim 10 which further comprises washing the filtered trimetrexate-DMF adduct with a C.sub.2 to C.sub.4 alcohol.

12. The method of claim 1 wherein in step (c), the trimetrexate-DMF adduct is converted into trimetrexate hydrochloride via a trimetrexate gluconate intermediate.

13. The method of claim 11 wherein said trimetrexate gluconate intermediate is produced by contacting the trimetrexate-DMF adduct with a source of gluconate.

14. The method of claim 11 wherein the trimetrexate gluconate intermediate is converted into trimetrexate hydrochloride using acetic acid and an aqueous sodium chloride solution to crystallize trimetrexate hydrochloride.

15. The method of claim 14 which further comprises heating the trimetrexate gluconate solution.

16. The method of claim 14 which further comprises filtering the trimetrexate hydrochloride.

17. The method of claim 16 which further comprises washing the filtered trimetrexate hydrochloride with water, a C.sub.2 to C.sub.4 alcohol, or a mixture thereof.

18. The method of claim 1 wherein step (d) comprises heating trimetrexate hydrochloride in a mixture of water and a C.sub.2 to C.sub.4 alcohol and raising the pH of the suspension to precipitate trimetrexate monohydrate.

19. The method of claim 18 which further comprises filtering, washing, and drying under vacuum the trimetrexate monohydrate.

20. The method of claim 1 which further comprises sieving and optionally blending the trimetrexate monohydrate.

21. A method of producing 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate comprising:

a. converting quinazoline aldehyde formate or quinazoline aldehyde diformate to 2,4-diamino-5-methyl-6-quinazoline carboxaldehyde hydrate;

b. coupling the 2,4-diamino-5-methyl-6-quinazoline carboxaldehyde hydrate with trimethoxyaniline to produce 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)methyl] quinazoline;

c. reducing 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)methyl] quinazoline to trimetrexate acetate hydrate; and

d. preparing pure trimetrexate monohydrate by treating trimetrexate acetate hydrate with ammonia and purifying the trimetrexate monohydrate product.

22. The method of claim 21 wherein step (a) comprises:

heating a solution of quinazoline aldehyde formate or diformate in the presence of EDTA, triethylamine and an amount of ammonia sufficient to give the solution a basic pH, to a reflux temperature and for a time sufficient to crystallize the 2,4-diamino-5-methyl-6-quinazoline carboxaldehyde hydrate.

23. The method of claim 22 wherein the solution of quinazoline aldehyde formate or diformate is prepared in a polar aqueous solvent.

24. The method of claim 23 wherein the polar aqueous solvent is water, a C.sub.2 to C.sub.4 alcohol, or a mixture thereof.

25. The method of claim 24 wherein the solvent is a mixture of n-butanol and water.

26. The method of claim 25 wherein the solvent is a mixture of n-butanol and water in a ratio of 0.5:1 to 3:1.

27. The method of claim 22 wherein the basic pH is about 8.0 to about 10.0, the reflux temperature is about 70.degree. C. to about 100.degree. C., and the time is about 5 to 60 minutes.

28. The method of claim 22 which further comprises filtering the 2,4-diamino-5-methyl-6-quinazoline carboxaldehyde hydrate.

29. The method of claim 24 which further comprises washing the 2,4-diamino-5-methyl-6-quinazoline carboxaldehyde hydrate with at least one portion of a C.sub.2 to C.sub.4 alcohol and at least one portion of water.

30. The method of claim 21 wherein step (b) comprises: heating the 2,4-diamino-5-methyl-6-quinazoline carboxaldehyde hydrate in a mixture of butanol and toluene to an azeotropic point; and distilling off the water of hydration to leave a phase containing 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)methyl] quinazoline.

31. The method of claim 30 which further comprises filtering the 2,4-diamino-5-methyl--6-[(3,4,5-trimethoxyphenylimino)methyl] quinazoline.

32. The method of claim 31 which further comprises washing the filtered 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)methyl] quinazoline with butanol and an ether.

33. The method of claim 21 wherein step (c) comprises heating the 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)methyl]quinazoline in a mixture of tetrahydrofuran and water in the presence of a reducing agent to produce a crude trimetrexate base, and converting the crude trimetrexate base to trimetrexate acetate.

34. The method of claim 33 wherein the reducing agent is sodium borohydride or an aqueous solution of sodium borohydride.

35. The method of claim 34 wherein the aqueous sodium borohydride is added gradually over a period of from one to ten hours.

36. The method of claim 21 wherein step (c) is carried out under an inert gas selected from the group consisting of nitrogen, argon and helium.

37. The method of claim 33 which further comprises distilling off about 90% of the tetrahydrofuran; adding alcohol and water; further distilling off tetrahydrofuran, alcohol and water; and cooling to produce a two-phase system containing the crude trimetrexate base.

38. The method of claim 33 wherein the step of converting the crude trimetrexate base to trimetrexate acetate comprises: heating the crude trimetrexate base in a polar solvent or solvent mixture; adding lactic acid, acetic acid, tonsil and a catalytic amount of activated charcoal; filtering to give a filtrate; heating the filtrate in the presence of sodium acetate and acetic acid; cooling the filtrate; and vacuum filtering to obtain trimetrexate acetate.

39. The method of claim 38 which further comprises washing the trimetrexate acetate with acetic acid.

40. The method of claim 21 wherein in step (d) the trimetrexate acetate is converted to trimetrexate monohydrate via a 2-methoxypropanol adduct.

41. The method of claim 40 wherein the 2-methoxypropanol adduct is produced by: heating trimetrexate acetate with ascorbic acid and ammonia in an aqueous alcohol; filtering to give a filtrate; raising the pH and cooling the filtrate to obtain a suspension of 2-methoxypropanol trimetrexate adduct; and filtering and washing the adduct with at least one portion of water and at least one portion of 2-propanol.

42. The method of claim 41 wherein said adduct is washed.

43. The method of claim 41 wherein said aqueous alcohol is butanol-water.

44. The method of claim 41 wherein the filtering step is carried out under pressure.

45. The method of claim 41 which further comprises purifying the 2-methoxypropanol adduct.

46. The method of claim 40 wherein the 2-methoxypropanol adduct is converted to trimetrexate monohydrate by: preparing a solution of the 2-methoxypropanol adduct with a solvent comprising a mixture of a C.sub.2 to C.sub.4 alcohol and water; heating to a reflux temperature; and cooling to crystallize trimetrexate monohydrate.

47. The method of claim 46 which further comprises vacuum filtering and washing the trimetrexate monohydrate with water.

48. The method of claim 46 which further comprises drying the trimetrexate monohydrate under vacuum.

49. The method of claim 47 wherein the drying takes place at a pressure of about 1 to 50 mbar, a temperature of about 40 to 80.degree. C., and for a time of about 2 to 40 hours.

50. The method of claim 21 which further comprises sieving and blending the trimetrexate monohydrate.

51. A compound having the formula: ##STR12##

or pharmaceutically acceptable salts, solvates or hydrates thereof.

52. A compound having the formula: ##STR13##

or pharmaceutically acceptable salts, solvates or hydrates thereof.

53. A compound having the formula: ##STR14##

or pharmaceutically acceptable salts, solvates or hydrates thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc